DLX2-DT

Across TCGA pan-cancer cohorts, DLX2-DT RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated DLX2-DT data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher DLX2-DT RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DLX2-DT expression acts as an unfavorable survival marker, although some lineages such as ESCA and BRCA show a favorable association.

ACC, KIRC, and KICH are the cancer types where DLX2-DT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.206	0.708	<.001	131	view →
KIRC	DFS	Quartile	II,III,IV	0.653	0.832	<.001	119	view →
KICH	OS	Tertile	All	0.547	0.931	<.001	103	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	63	view →
MESO	DFS	Quartile	All	0.255	0.415	.009	60	view →
LIHC	OS	Tertile	All	0.373	0.561	<.001	56	view →
LGG	OS	Tertile	All	0.728	0.845	<.001	46	view →
KIRP	DFS	Tertile	All	0.309	0.645	<.001	30	view →
PAAD	DFS	Tertile	All	0.322	0.513	.006	27	view →
ESCA	DFS	Tertile	All	0.883	0.358	.009	21	view →
OV	OS	Tertile	III,IV	0.247	0.345	.009	20	view →
BLCA	DFS	Tertile	All	0.201	0.457	.010	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

DLX2-DT–ACC (DFS)

Open the ACC breakdown →